JGP Global Gestao de Recursos Ltda. bought a new position in Sarepta Therapeutics Inc (NASDAQ:SRPT) in the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 2,475 shares of the biotechnology company’s stock, valued at approximately $319,000.
Several other hedge funds and other institutional investors also recently bought and sold shares of SRPT. Amundi Pioneer Asset Management Inc. grew its holdings in shares of Sarepta Therapeutics by 32.8% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 154,611 shares of the biotechnology company’s stock valued at $18,428,000 after purchasing an additional 38,194 shares during the period. US Bancorp DE grew its stake in shares of Sarepta Therapeutics by 16.1% in the 2nd quarter. US Bancorp DE now owns 1,193 shares of the biotechnology company’s stock valued at $181,000 after buying an additional 165 shares during the period. Private Advisor Group LLC purchased a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at approximately $255,000. Paloma Partners Management Co purchased a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at approximately $312,000. Finally, California State Teachers Retirement System increased its holdings in shares of Sarepta Therapeutics by 6.9% during the 2nd quarter. California State Teachers Retirement System now owns 112,277 shares of the biotechnology company’s stock worth $17,060,000 after buying an additional 7,255 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.
SRPT traded down $1.08 during mid-day trading on Friday, hitting $112.60. 30,388 shares of the stock were exchanged, compared to its average volume of 852,647. The firm’s fifty day moving average is $125.37 and its two-hundred day moving average is $111.04. Sarepta Therapeutics Inc has a 1-year low of $72.05 and a 1-year high of $158.80. The company has a market cap of $8.82 billion, a PE ratio of -13.17 and a beta of 2.27. The company has a current ratio of 6.31, a quick ratio of 5.54 and a debt-to-equity ratio of 0.49.
A number of research firms recently commented on SRPT. Barclays reiterated a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a report on Sunday, December 15th. Goldman Sachs Group reissued a “buy” rating and set a $180.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, December 24th. Guggenheim initiated coverage on Sarepta Therapeutics in a research report on Friday, November 1st. They issued a “buy” rating and a $183.00 target price on the stock. Leerink Swann reaffirmed a “buy” rating and issued a $216.00 price target on shares of Sarepta Therapeutics in a research note on Thursday. Finally, Oppenheimer reiterated a “hold” rating on shares of Sarepta Therapeutics in a report on Monday, December 30th. One analyst has rated the stock with a sell rating, two have issued a hold rating and twenty-four have given a buy rating to the stock. Sarepta Therapeutics has an average rating of “Buy” and a consensus price target of $197.81.
In related news, CFO Sandesh Mahatme sold 125,000 shares of Sarepta Therapeutics stock in a transaction on Friday, December 13th. The stock was sold at an average price of $125.50, for a total value of $15,687,500.00. Following the completion of the transaction, the chief financial officer now directly owns 34,498 shares in the company, valued at $4,329,499. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Alexander Cumbo sold 42,000 shares of Sarepta Therapeutics stock in a transaction on Friday, December 13th. The shares were sold at an average price of $125.50, for a total value of $5,271,000.00. Following the completion of the transaction, the executive vice president now owns 13,888 shares of the company’s stock, valued at $1,742,944. The disclosure for this sale can be found here. Insiders sold 192,000 shares of company stock valued at $23,583,500 in the last 90 days. Company insiders own 6.60% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Read More: Treasury Bonds
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.